Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Glutamate receptor ionotropic NMDA subunit 2A (GluN2A), encoded by the GRIN2A gene, is a critical component of the N-methyl-D-aspartate (NMDA) receptor complex, a ligand-gated ion channel essential for excitatory neurotransmission in the brain [1, 3]. NMDA receptors are heterotetramers typically composed of two GluN1 subunits and two GluN2 subunits; the GluN2A subunit specifically contains the orthosteric binding site for the primary excitatory neurotransmitter, glutamate [2, 4]. This glutamate binding site is located within the extracellular ligand-binding domain (LBD) formed by the S1 and S2 segments of the protein [4]. Activation of this site, alongside the glycine site on GluN1, triggers a conformational change that opens the ion channel pore, allowing the influx of calcium and sodium ions [4, 5]. This process is fundamental to synaptic plasticity, long-term potentiation (LTP), and cognitive functions such as learning and memory. Dysregulation or mutations in the GluN2A subunit are linked to various neurological conditions, including epilepsy-aphasia spectrum disorders, schizophrenia, and neurodegenerative diseases [3, 5]. Pharmacological targeting of the GluN2A glutamate site or its allosteric sites aims to modulate excitatory signaling, with research focusing on both competitive antagonists for neuroprotection and positive allosteric modulators for cognitive enhancement [2, 4].
Competitive antagonism at the orthosteric glutamate binding site, uncompetitive channel blockade, or allosteric modulation of the NMDA receptor complex to regulate calcium-permeable ion flow.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate receptor ionotropic NMDA subunit 2A (GluN2A) (GluN2A).